The current state of bench-to-bedside translation of polygenic risk scores (PRS) is reviewed and it is shown that quality standards must be established to ensure that the potential of PRS can be effectively translated into routine clinical practice.
Abstract
Background
Common diseases are largely caused by the combined contributions of genetic and environmental risk factors. On the genetic side, numerous variants contribute to disease susceptibility, resulting in a substantial polygenic component of disease risk. Many such variants have already been identified. Polygenic risk scores (PRS), which aggregate the effects of these variants, enable more precise estimation of an individual's disease risk. We review the current state of bench-to-bedside translation of PRS.
Methods
This review is based on publications retrieved by a selective PubMed literature search using predefined search terms relevant to PRS.
Results
Studies across a range of diseases have shown that PRS can markedly influence the assessment of disease risk, enabling the identification of individuals at high risk. The predictive value of PRS can be improved by integrating them into established clinical risk models; this is the area of application in which the implementation of PRS in clinical practice is currently most advanced. For example, studies on coronary heart disease (CHD) and on breast and pancreatic cancer have shown that integrating PRS into clinical risk models changes personalized recommendations for primary and secondary prevention. Depending on the study, this affects 24% (CHD) to 25% (breast cancer) of individuals in the respective clinical risk groups. A major limitation is that most PRS are based on data from European populations, and their predictive value may be lower in individuals of other ancestral backgrounds. Moreover, quality standards must be established to ensure that the potential of PRS can be effectively translated into routine clinical practice.
Conclusion
As genetic data continue to grow, the predictive value of PRS is expected to increase further. PRS are therefore likely to become an integral component of risk prediction in preventive and precision medicine.
The reasons for the slow pace of the diffusion of polygenic risk scores, along with the related field of pharmacogenomics, may be useful in clinical practice for the prevention and treatment of common diseases are reviewed.
David J. Hunter, Michael Inouye· New England Journal of Medic...· 1 citation
This review outlines four major PRS-informed design strategies: tail sampling based on PRS extremes; discordance sampling based on mismatch between phenotype and PRS-implied risk; conditional and stratified genome-wide association analyses using PRS to adjust for / partition background risk; and residual phenotype anal...
Hui-Qi Qu, H. Hakonarson· Human Genetics· 0 citations
This review summarizes the principles of PRS, the main sources of variability between models, and its potential applications in risk stratification and personalized cancer screening and addresses limitations in transferability, the need for calibration, and the currently limited evidence for improvements in hard clinic...
Adéla Mišove, E. Macháčková, Klára Nováková et al.· Klinicka onkologie· 0 citations
Investigating the utility of genome-wide association study - derived PRS and pathway-specific PRS in the Latvian population and demonstrating superior discrimination compared to pathway-specific PRS found incorporation of PRS enhances early-onset CAD risk prediction.
E. Kanašniece, Elita Ozola, L. Bardina et al.· American Heart Journal Plus:...· 0 citations
It is shown that the published hypercholesterolemia PRS (PGS000936) can effectively stratify risk and identify individuals with a high genetic burden in a real-world German clinical setting, supporting its clinical utility when appropriately calibrated for the local population.
L. Bundalian, A. Velluva, E. Gjermeni et al.· medRxiv· 0 citations
BCa and inherited genetic susceptibility jointly contribute to increased risk of multiple common diseases, supporting the integration of genetic risk stratification into survivorship care.
Annabelle Ashworth, Zhu-Qing Shi, Huy Tran et al.· JNCI Cancer Spectrum· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.